BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Warrington S, Baisley K, Boyce M, Tejura B, Morocutti A, Miller N. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther. 2002;16:1301-1307. [PMID: 12144580 DOI: 10.1046/j.1365-2036.2002.01292.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther. 2003;17:1507-1514. [PMID: 12823153 DOI: 10.1046/j.1365-2036.2003.01496.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 91] [Article Influence: 5.7] [Reference Citation Analysis]
2 Graham DY, Tansel A. Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency. Clin Gastroenterol Hepatol 2018;16:800-808.e7. [PMID: 28964908 DOI: 10.1016/j.cgh.2017.09.033] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 12.8] [Reference Citation Analysis]
3 Robinson M, Barone J. Review article: comparative pharmacodynamic review of rabeprazole - focus on day 1 data. Aliment Pharmacol Ther Symp Series 2006;2:315-26. [DOI: 10.1111/j.1746-6342.2006.00062.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Varannes SBD, Sacher-Huvelin S, Vavasseur F, Masliah C, Rhun ML, Aygalenq P, Bonnot-Marlier S, Lequeux Y, Galmiche JP. Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: Results of a study in a primary care setting. World J Gastroenterol 2006; 12(16): 2569-2573 [PMID: 16688803 DOI: 10.3748/wjg.v12.i16.2569] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
5 Bardhan KD. Intermittent and on-Demand Use of Proton Pump Inhibitors in The Management of Symptomatic Gastroesophageal Reflux Disease. American Journal of Gastroenterology 2003;98:S40-8. [DOI: 10.1016/s0002-9270(03)00014-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 5] [Article Influence: 2.1] [Reference Citation Analysis]
6 Verheijen RB, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N. Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing. Clin Pharmacokinet 2017;56:987-97. [PMID: 28185218 DOI: 10.1007/s40262-017-0510-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 12.0] [Reference Citation Analysis]
7 Qasim A, O’morain CA, O’connor HJ. Helicobacter pylori eradication: role of individual therapy constituents and therapy duration. Fundamental & Clinical Pharmacology 2009;23:43-52. [DOI: 10.1111/j.1472-8206.2008.00635.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
8 Katz P, Kahrilas PJ, Johnson DA, Lind T, Röhss K, Traxler B, Hugo V, Dent J. Daytime intragastric acid control: post hoc analyses of esomeprazole 20 mg and over-the-counter proton-pump inhibitors. Therap Adv Gastroenterol 2015;8:322-30. [PMID: 26557888 DOI: 10.1177/1756283X15592583] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
9 R??hss K, Wilder-smith C, Naucl??r E, Jansson L. Esomeprazole 20mg Provides More Effective Intragastric Acid Control than Maintenance-Dose Rabeprazole, Lansoprazole or Pantoprazole in Healthy Volunteers: . Clinical Drug Investigation 2004;24:1-7. [DOI: 10.2165/00044011-200424010-00001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
10 Calvet X, Gomollón F. What is potent acid inhibition, and how can it be achieved? Drugs. 2005;65 Suppl 1:13-23. [PMID: 16335854 DOI: 10.2165/00003495-200565001-00004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
11 Wang Y, Yuan Y, Meng L, Fan H, Xu J, Zhang H, Wang M, Yuan H, Ou N, Zhang H, Chao Y, Shi R. Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. Eur J Clin Pharmacol 2011;67:25-31. [PMID: 21110014 DOI: 10.1007/s00228-010-0949-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
12 Galmiche JP, Sacher-Huvelin S, Bruley des Varannes S, Vavasseur F, Taccoen A, Fiorentini P, Homerin M. A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers. Aliment Pharmacol Ther 2005;21:575-82. [PMID: 15740541 DOI: 10.1111/j.1365-2036.2005.02381.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
13 Fock K, Teo E, Ang T, Chua T, Ng T, Tan Y. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: A randomized, double-blind study in urban Asia. World J Gastroenterol 2005; 11(20): 3091-3098 [PMID: 15918196 DOI: 10.3748/wjg.v11.i20.3091] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
14 Klotz U, Schwab M, Treiber G. CYP2C19 Polymorphism and Proton Pump Inhibitors: CYP2C19 AND PROTON PUMP INHIBITORS. Basic & Clinical Pharmacology & Toxicology 2004;95:2-8. [DOI: 10.1111/j.1600-0773.2004.pto950102.x] [Cited by in Crossref: 112] [Cited by in F6Publishing: 102] [Article Influence: 6.6] [Reference Citation Analysis]
15 Pace F, Annese V, Prada A, Zambelli A, Casalini S, Nardini P, Bianchi Porro G. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole. Dig Liver Dis. 2005;37:741-750. [PMID: 16024305 DOI: 10.1016/j.dld.2005.04.026] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
16 Morelli G, Chen H, Rossiter G, Rege B, Lu Y. An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers. Aliment Pharmacol Ther 2011;33:845-54. [PMID: 21272047 DOI: 10.1111/j.1365-2036.2011.04580.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
17 Bytzer P, Blum A, De Herdt D, Dubois D. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2004;20:181-188. [PMID: 15233698 DOI: 10.1111/j.1365-2036.2004.01999.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 3.8] [Reference Citation Analysis]
18 Zhang W, Wu J, Atkinson SN. Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects. J Clin Pharmacol 2009;49:444-54. [PMID: 19318694 DOI: 10.1177/0091270008330155] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
19 Sloan S. Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003;98:S49-55. [PMID: 12644031 DOI: 10.1016/s0002-9270(03)00015-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
20 Horn J. Review article: understanding the pharmacodynamic and pharmacokinetic differences between proton pump inhibitors - focus on pKa and metabolism. Aliment Pharmacol Ther Symp Series 2006;2:340-50. [DOI: 10.1111/j.1746-6342.2006.00065.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
21 Warrington S, Baisley K, Dunn K, Boyce M, Morocutti A. Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects. Eur J Clin Pharmacol 2006;62:685-91. [PMID: 16850327 DOI: 10.1007/s00228-006-0148-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
22 Dhillo WS, Jayasena CN, Jackson JE, Lynn JA, Bloom SR, Meeran K, Todd JF. Localization of gastrinomas by selective intra-arterial calcium injection in patients on proton pump inhibitor or H2 receptor antagonist therapy: . European Journal of Gastroenterology & Hepatology 2005;17:429-33. [DOI: 10.1097/00042737-200504000-00006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
23 de Boer W, de Wit N, Geldof H, Hazelhoff B, Bergmans P, Smout A, Tytgat G. Does Helicobacter pylori infection influence response rate or speed of symptom control in patients with gastroesophageal reflux disease treated with rabeprazole? Scand J Gastroenterol 2006;41:1147-54. [PMID: 16990199 DOI: 10.1080/00365520600741546] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
24 Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 2003;63:2739-54. [PMID: 14664653 DOI: 10.2165/00003495-200363240-00004] [Cited by in Crossref: 117] [Cited by in F6Publishing: 102] [Article Influence: 6.9] [Reference Citation Analysis]
25 Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, Brockmöller J. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009;65:19-31. [PMID: 18925391 DOI: 10.1007/s00228-008-0576-5] [Cited by in Crossref: 125] [Cited by in F6Publishing: 107] [Article Influence: 9.6] [Reference Citation Analysis]
26 Armstrong D, James C, Camacho F, Chen Y, Horbay GL, Teixeira B, Husein-Bhabha FA. Oral rabeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. Aliment Pharmacol Ther 2007;25:185-96. [PMID: 17116123 DOI: 10.1111/j.1365-2036.2006.03160.x] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
27 Robinson M. Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. Int J Clin Pract. 2005;59:709-715. [PMID: 15924600 DOI: 10.1111/j.1368-5031.2005.00517.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 48] [Article Influence: 3.9] [Reference Citation Analysis]
28 Maiti R, Jaida J, Israel PL, Koyagura N, Mukkisa S, Palani A. Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety. J Pharmacol Pharmacother 2011;2:150-7. [PMID: 21897706 DOI: 10.4103/0976-500X.83278] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
29 Wire MB, Shelton MJ, Studenberg S. Fosamprenavir: Clinical Pharmacokinetics and Drug Interactions of the Amprenavir Prodrug. Clinical Pharmacokinetics 2006;45:137-68. [DOI: 10.2165/00003088-200645020-00002] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 4.7] [Reference Citation Analysis]
30 Norris V, Baisley K, Dunn K, Warrington S, Morocutti A. Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers: COMBINED ANALYSIS OF RABEPRAZOLE VS. ESOMEPRAZOLE ON INTRAGASTRIC pH. Alimentary Pharmacology & Therapeutics 2007;25:501-10. [DOI: 10.1111/j.1365-2036.2006.03221.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
31 Bytzer P, Morocutti A, Kennerly P, Ravic M, Miller N; ROSE Trial Investigators. Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment. Scand J Gastroenterol 2006;41:1132-40. [PMID: 16990197 DOI: 10.1080/00365520600615781] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
32 Tan AR, Gibbon DG, Stein MN, Lindquist D, Edenfield JW, Martin JC, Gregory C, Suttle AB, Tada H, Botbyl J, Stephenson JJ. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Cancer Chemother Pharmacol 2013;71:1635-43. [PMID: 23636448 DOI: 10.1007/s00280-013-2164-3] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 8.8] [Reference Citation Analysis]
33 Sugimoto M, Furuta T. Efficacy of esomeprazole in treating acid-related diseases in Japanese populations. Clin Exp Gastroenterol. 2012;5:49-59. [PMID: 22649281 DOI: 10.2147/ceg.s23926] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
34 Pallotta S, Pace F, Marelli S. Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease. Expert Review of Gastroenterology & Hepatology 2014;2:509-22. [DOI: 10.1586/17474124.2.4.509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
35 de Korwin J, Ducrotté P, Vallot T. Les nouveaux inhibiteurs de la pompe à protons, un progrès dans la prise en charge des maladies acido-peptiques ? La Presse Médicale 2004;33:746-54. [DOI: 10.1016/s0755-4982(04)98731-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
36 Warrington S, Baisley K, Lee D, Lomax K, Delemos B, Boyce M, Morocutti A. Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn. Aliment Pharmacol Ther. 2007;25:511-517. [PMID: 17270007 DOI: 10.1111/j.1365-2036.2006.03196.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
37 Polimeni G, Cutroneo P, Gallo A, Gallo S, Spina E, Caputi AP. Rabeprazole and Psychiatric Symptoms. Ann Pharmacother 2007;41:1315-7. [DOI: 10.1345/aph.1k134] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
38 Lim P, Goh K. Review Article: Efficacy and safety of rabeprazole in treating gastroesophageal reflux disease. J Gastroenterol Hepatol 2004;19:S61-8. [DOI: 10.1111/j.1440-1746.2004.03592.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
39 Orr WC. Therapeutic options in the treatment of nighttime gastroesophageal reflux. Digestion 2005;72:229-38. [PMID: 16319458 DOI: 10.1159/000089957] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
40 Robinson M. Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders. Aliment Pharmacol Ther. 2004;20 Suppl 6:30-37. [PMID: 15496216 DOI: 10.1111/j.1365-2036.2004.02163.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
41 Anjiki H, Mukaisho K, Kadomoto Y, Doi H, Yoshikawa K, Nakayama T, Vo DT, Hattori T, Sugihara H. Adenocarcinoma arising in multiple hyperplastic polyps in a patient with Helicobacter pylori infection and hypergastrinemia during long-term proton pump inhibitor therapy. Clin J Gastroenterol 2017;10:128-36. [DOI: 10.1007/s12328-017-0714-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
42 Zannikos PN, Doose DR, Leitz GJ, Rusch S, Gonzalez MD, Solanki B, Haddad I, Mulberg AE. Pharmacokinetics and tolerability of rabeprazole in children 1 to 11 years old with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2011;52:691-701. [PMID: 21478756 DOI: 10.1097/MPG.0b013e318207834d] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
43 Feng Z, Huang J, Xu Y, Zhang M, Hu S. Dissociative disorder induced by clarithromycin combined with rabeprazole in a patient with gastritis. J Int Med Res. 2013;41:239-243. [PMID: 23569151 DOI: 10.1177/0300060513475384] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
44 Kou D, Dwaraknath S, Fischer Y, Nguyen D, Kim M, Yiu H, Patel P, Ng T, Mao C, Durk M, Chinn L, Winter H, Wigman L, Yehl P. Biorelevant Dissolution Models for a Weak Base To Facilitate Formulation Development and Overcome Reduced Bioavailability Caused by Hypochlordyria or Achlorhydria. Mol Pharmaceutics 2017;14:3577-87. [DOI: 10.1021/acs.molpharmaceut.7b00593] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
45 Rogala BG, Charpentier MM, Nguyen MK, Landolf KM, Hamad L, Gaertner KM. Oral Anticancer Therapy: Management of Drug Interactions. J Oncol Pract 2019;15:81-90. [PMID: 30763198 DOI: 10.1200/JOP.18.00483] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 11.0] [Reference Citation Analysis]
46 Goh K. "On-demand" therapy for gastroesophageal reflux disease: Are current proton pump inhibitors good candidates? J Gastroenterol Hepatol 2006;21:S115-8. [DOI: 10.1111/j.1440-1746.2006.04714.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
47 Shelton MJ, Ford SL, Borland J, Lou Y, Wire MB, Min SS, Xue ZG, Yuen G. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. J Acquir Immune Defic Syndr 2006;42:61-7. [PMID: 16639341 DOI: 10.1097/01.qai.0000219770.97303.43] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
48 Thjodleifsson B. Review of rabeprazole in the treatment of gastro-oesophageal reflux disease. Expert Opinion on Pharmacotherapy 2005;5:137-49. [DOI: 10.1517/14656566.5.1.137] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]